TGTX
TG Therapeutics Inc
NASDAQ: TGTX · HEALTHCARE · BIOTECHNOLOGY
$57.16
+0.51% today
Updated 2026-09-21
Market cap
$8.75B
P/E ratio
20.86
P/S ratio
10.94x
EPS (TTM)
$2.74
Dividend yield
—
52W range
$27 – $59
Volume
2.1M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
5.7
Growth
C+5.5
Quality
C+8.0
Profitability
A5.0
Valuation
C+3/9
Piotroski F-Score
Weak
1.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →250 stocks currently score above 75
Price targets
Analyst target
$69.71
+21.96%
12-Month target
$30.20
-47.17%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy0 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 55.20% — above average
+ ROE 79.21% — strong efficiency
+ Free cash flow $21.02M — positive
+ Revenue growth 70.30% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 1.05 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.79M | $233.66M | $329.00M | $616.29M | $799.54M |
| Net income | $-223.81M | $12.67M | $23.38M | $447.18M | $7.78M |
| EPS | — | — | — | — | $2.74 |
| Free cash flow | $-176.18M | $-31.41M | $-40.56M | $-24.99M | $21.02M |
| Profit margin | -8,036.34% | 5.42% | 7.11% | 72.56% | 55.20% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-07 | CHARNEY, LAURENCE N | Sale | 500 | — |
| 2026-08-07 | CHARNEY, LAURENCE N | Sale | 450 | — |
| 2026-08-06 | CHARNEY, LAURENCE N | Sale | 5,100 | — |
Peer comparison
Smart narrative
TG Therapeutics Inc trades at $57.16. representing a P/E of 20.86x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.05, it sits in the distress. TTM revenue stands at $799.54M. with profit margins at 55.20%.
Frequently asked questions
What is TG Therapeutics Inc's stock price?
TG Therapeutics Inc (TGTX) trades at $57.16, on a P/E of 20.9x and a P/S of 10.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is TG Therapeutics Inc overvalued?
TG Therapeutics Inc carries a Smart Value Score of 56/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of TG Therapeutics Inc (TGTX)?
The 12-month analyst consensus target is $69.71, about 22.0% above the current $57.16. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is TG Therapeutics Inc's revenue?
TG Therapeutics Inc's trailing twelve-month revenue is $799.54M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
TG Therapeutics Inc's Altman Z-Score is 1.05, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.94x
ROE79.21%
Beta1.66
50D MA$53.45
200D MA$40.19
Shares out0.15B
Float0.14B
Short ratio—
Avg volume2.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—